Immune Checkpoints News Today

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion...

–In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion–

Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress.

- Interim results from Phase 2 innovaTV 207 trial of tisotumab vedotin in head and neck cancer to be presented -- Initial Phase 1 dose-escalation data for SEA-TGT monotherapy in advanced malignancies to be disclosed -- Preclinical data and discovery research underscore Seagen’s mission to innovate through next-gener...

At the 2023 American Association for Cancer Research (AACR) Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced it will be presenting five

Side effects/ toxicity of immunotherapy may be relieved by targeting interleukin-6 (IL-6) and immune checkpoint blockade while preserving anti-tumor immune response.

Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021 - JBI-1527, a potent, selective oral inhibitor of PD-L1 exhibited T-cell restoration and immune-mediated tumor growth suppression - Data support the further development of PRMT5 inhibitor JBI-778 and PD-L1 inhibitor JBI-1527 for the treatment of unmet need in oncology BEDMINSTER, N.J., April 10, 2021 ...

Posted on 244 Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during Week 1 of the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021. “At AACR 2021, we look forward to sharing clinical and pre-clinical data from INCB106385, our novel A2A/A2B adenosine receptor antagonist, and INCA00186, our novel CD73 ...

OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual Meeting Permanent Abstract Number: 1636 Title: Optimized antagonist anti-PD-1/IL-7 mutein bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity. Morello A., Seité M., Durand J, Thépenier V., Teppaz G., Pengam S., Wilhelm E., Desselle A., Girault I., Mary C., Poirier N. Session Type: E-Poste...

Share this article Share this article ResearchAndMarkets.coms offering. The Global Humanized Mice Model Market is projected to grow at a CAGR of more than 10% during 2020 - 2025 The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe. In addition to this, increasing investments for research in laboratories and institutes is positively impacting the growth of the market. The Global Humanized Mice Model Market...